tradingkey.logo
マヌケット
ニュヌス
分析
ツヌル
株匏スコア
株匏スコア



English
繁䜓䞭文
à¹„àž—àž¢
Tiếng việt
简䜓䞭文
Español
Português
Deutsch
한국얎
日本語

tradingkey.logo



Drugs Made In America Acquisition II Rights Exp 16 Sep 2030

DMIIR
0.100USD
0.0000.00%
取匕時間 ET15分遅れの株䟡
0.00時䟡総額
--盎近12ヶ月PER


Drugs Made In America Acquisition II Rights Exp 16 Sep 2030

0.100
0.0000.00%
抂芁金融分析䌁業名

抂芁

金融

分析

䌁業名

詳现情報 Drugs Made In America Acquisition II Rights Exp 16 Sep 2030 䌁業名

Drugs Made In America Acquisition II Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to search for business combination targets in the pharmaceutical industry. The Company is neither engaged in any operations nor generated any revenues.

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030の䌁業情報


䌁業コヌドDMIIR
䌚瀟名Drugs Made In America Acquisition II Corp
䞊堎日Sep 25, 2025
最高経営責任者「CEO」Stockwell (Lynn)
埓業員数- -
蚌刞皮類Right
決算期末- -
本瀟所圚地1 East Broward Boulevard
郜垂FT LAUDERDALE
蚌刞取匕所NASDAQ OMX - NASDAQ BASIC
囜United States of America
郵䟿番号33301
電話番号19548703099
りェブサむト
䌁業コヌドDMIIR
䞊堎日Sep 25, 2025
最高経営責任者「CEO」Stockwell (Lynn)

Drugs Made In America Acquisition II Rights Exp 16 Sep 2030の経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
詳现を芋る
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Ms. Lynn Stockwell
Ms. Lynn Stockwell
Executive Chairman of the Board, Chief Executive Officer
Executive Chairman of the Board, Chief Executive Officer
--
--
Mr. Glenn Worman
Mr. Glenn Worman
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--
Dr. Catherine Do
Dr. Catherine Do
Independent Director
Independent Director
--
--
Dr. G. Sridhar Prasad
Dr. G. Sridhar Prasad
Independent Director
Independent Director
--
--
Mr. Myron W. Shulgan
Mr. Myron W. Shulgan
Independent Director
Independent Director
--
--
Mr. Saleem Elmasri, CPA
Mr. Saleem Elmasri, CPA
Chief Financial Officer, Principal Financial and Accounting Officer
Chief Financial Officer, Principal Financial and Accounting Officer
--
--

収益内蚳

䌚瀟から関連デヌタがただ開瀺されおいたせん。
䌚瀟から関連デヌタがただ開瀺されおいたせん。
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Thu, Feb 19
曎新時刻: Thu, Feb 19
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
他の
100.00%
株䞻統蚈
株䞻統蚈
比率
他の
100.00%
皮類
株䞻統蚈
比率
他の
100.00%

機関投資家保有株


曎新時刻: Sun, Feb 1
曎新時刻: Sun, Feb 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2025Q4
3
958.51K
0.00%
+958.51K

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
デヌタなし
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
デヌタなし
日付
配圓萜ち日
皮類
比率
デヌタなし
KeyAI
î™